Ionis Pharmaceuticals, Inc. (IONS)
| Previous close | 41.84 |
| Open | 41.97 |
| Bid | 42.25 x 100 |
| Ask | 42.38 x 500 |
| Day's range | 41.59 - 42.72 |
| 52-week range | 34.32 - 54.44 |
| Volume | |
| Avg. volume | 1,079,261 |
| Market cap | 6.167B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.56 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 55.95 |
PR NewswireIonis to hold first quarter 2024 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.
- PR Newswire
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprote
- PR Newswire
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
